Pfizer’s Ibrance And The Realities Of 'Real-World' Evidence

 
• By Michael McCaughan
  
Boy-virtual-glasses
The US FDA's reliance on real-world evidence may have been less than meets the eye in the case of the supplemental indication for Pfizer’s Ibrance.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from Pathways & Standards